However, in HER2-overexpressing or mutant NSCLC cells, the inhibitory activity of PCC0208027 (IC50 = 6.07 nM for Calu-3 and IC50 = 5.97 nM for NCI-H1781) was significantly better than erlotinib and osimertinib, and similar to poziotinib. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.